We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+30.04%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$647M
AUM Growth
-$1.41M
(-0.22%)
Cap. Flow
-$92.7M
Cap. Flow
% of AUM
-14.32%
Top 10 Holdings %
Top 10 Hldgs %
48.48%
Holding
76
New
6
Increased
14
Reduced
49
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alkermes
ALKS
|
+$17.1M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$13.1M |
| 3 |
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
|
+$8.98M |
| 4 |
EPRS
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
|
+$6.6M |
| 5 |
Heron Therapeutics
HRTX
|
+$6.43M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$33.6M |
| 2 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
+$31.8M |
| 3 |
Tempest Therapeutics
TPST
|
+$12.9M |
| 4 |
Puma Biotechnology
PBYI
|
+$11.3M |
| 5 |
KITE
Kite Pharma, Inc.
KITE
|
+$10.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 72.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RCPT
1
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $64.4M | 9.95% |
390,312
-251,488
| -39% | -$31.8M |
|
|
2
Alkermes
ALKS
$8.11B
| $42.7M | 6.6% |
700,000
+250,000
| +56% | +$17.1M |
|
|
3
Puma Biotechnology
PBYI
$398M
| $39.5M | 6.1% |
167,300
-52,700
| -24% | -$11.3M |
|
|
EGRX
4
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $30M | 4.64% |
716,500
+316,500
| +79% | +$8.98M |
|
|
5
Bristol-Myers Squibb
BMY
$129B
| $29.6M | 4.58% |
459,000
+209,000
| +84% | +$13.1M |
|
6
Neurocrine Biosciences
NBIX
$18.2B
| $28.5M | 4.41% |
718,900
-281,100
| -28% | -$10.1M |
|
|
PTLA
7
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $21.8M | 3.37% |
574,500
-25,500
| -4% | -$876K |
|
|
SRNE
8
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $19.1M | 2.95% |
1,652,912
-97,088
| -6% | -$1.12M |
|
|
DYAX
9
DELISTED
DYAX CORPORATION
DYAX
| $19.1M | 2.95% |
1,138,900
-361,100
| -24% | -$5.62M |
|
|
QTNT
10
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $19M | 2.94% |
27,978
+478
| +2% | +$302K |
|
|
11
Heron Therapeutics
HRTX
$93.4M
| $18.5M | 2.86% |
1,270,000
+570,000
| +81% | +$6.43M |
|
|
12
Tempest Therapeutics
TPST
$14.3M
| $16.1M | 2.48% |
158
-97
| -38% | -$12.9M |
|
|
RGLS
13
DELISTED
Regulus Therapeutics
RGLS
| $15.2M | 2.35% |
7,471
-1,696
| -19% | -$3.69M |
|
|
ADXS
14
DELISTED
Advaxis Inc
ADXS
| $14.1M | 2.18% |
65,025
+9,058
| +16% | +$1.39M |
|
15
Ardelyx
ARDX
$1.24B
| $13.3M | 2.05% |
1,013,785
-39,715
| -4% | -$744K |
|
|
TSRO
16
DELISTED
TESARO, Inc.
TSRO
| $11M | 1.7% |
191,250
-108,750
| -36% | -$5.12M |
|
|
KERX
17
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $10.5M | 1.62% |
826,000
-174,000
| -17% | -$2.24M |
|
18
Novavax
NVAX
$1.21B
| $10.2M | 1.58% |
61,915
-13,085
| -17% | -$2.12M |
|
19
DexCom
DXCM
$29B
| $9.54M | 1.47% |
612,000
-188,000
| -24% | -$2.84M |
|
20
Karyopharm Therapeutics
KPTI
$155M
| $9.21M | 1.42% |
20,066
-5,601
| -22% | -$2.41M |
|
|
ALDR
21
DELISTED
Alder Biopharmaceuticals
ALDR
| $9.16M | 1.42% |
317,475
+67,475
| +27% | +$1.85M |
|
|
CMRX
22
DELISTED
Chimerix, Inc.
CMRX
| $8.65M | 1.34% |
229,500
-170,500
| -43% | -$6.77M |
|
23
Omeros
OMER
$845M
| $8.56M | 1.32% |
388,500
-193,800
| -33% | -$4.42M |
|
|
EPRS
24
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
| $8.03M | 1.24% |
896,600
+821,600
| +1,095% | +$6.6M |
|
|
PFNX
25
DELISTED
Pfenex Inc.
PFNX
| $7.57M | 1.17% |
+474,900
| New | +$5.23M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
CCA
LBC
C
Cormorant Asset Management's Q1 2015 Portfolio in Review
As of Q1 2015, Cormorant Asset Management held 76 positions worth $647M, down 0.22% from $649M the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Cormorant Asset Management withdrew a net $92.7M in Q1 2015, closing 5 positions and reducing 49 holdings. Its most notable exit was Celgene Corp, an estimated $33.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 69% a quarter earlier.
Against the trend, Cormorant Asset Management opened a new position in Epizyme, Inc worth $5M.
- Cormorant Asset Management's largest Q1 2015 buy was Epizyme, Inc: 266,250 shares worth $5M.
- Cormorant Asset Management added most to Alkermes in Q1 2015, an estimated $17.1M increase.
- Cormorant Asset Management's biggest Q1 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $31.8M.
- Cormorant Asset Management fully exited Celgene Corp in Q1 2015, selling an estimated $33.6M.
- Cormorant Asset Management's ten largest holdings make up 48% of its $647M portfolio in Q1 2015.
- Cormorant Asset Management opened 6 new positions and closed 5 in Q1 2015.
- Cormorant Asset Management's portfolio value fell 0.22% quarter-over-quarter to $647M.
Based on Cormorant Asset Management's 13F filing for Q1 2015, filed 15 May 2015.